Celcuity (CELC)
(Delayed Data from NSDQ)
$15.77 USD
-0.56 (-3.43%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $15.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CELC 15.77 -0.56(-3.43%)
Will CELC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CELC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELC
Why Celcuity (CELC) Might Surprise This Earnings Season
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet
CELC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CELC
Buy Rating Affirmed: Optimism for Celcuity’s Pipeline and Financial Stability Amid Clinical Trial Progress
Cisco, Walmart report quarterly earnings beats: Morning Buzz
Celcuity price target lowered by $1 at Stifel, here's why
Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ) and Celcuity (CELC)
Analysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)